51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04523506 (ClinicalTrials.gov) | May 8, 2020 | 19/7/2020 | The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma | The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma | Scleroderma | Biological: Botulinum toxin(Botox) | University of Texas Southwestern Medical Center | NULL | Completed | 18 Years | 65 Years | All | 17 | Early Phase 1 | United States |